Currently, there are major gaps in scientific knowledge concerning COVID-19 risk factors, transmission dynamics, seasonal and geographic patterns, correlations between immune markers and reinfection, and long-term immunologic, physiologic, and clinical sequelae of infection. A unique dimension of the COVID-19 pandemic is the high percentage of infected individuals with insufficient symptoms to require clinical care. Monitoring clinical volumes and establishing patient registries, while helpful, will miss a large reservoir of individuals that may be driving transmission rates and will be a major indicator of changes in the epidemic. To perform this surveillance, Vysnova along with the COVID-19 Community Partnership team is implementing a natural history study using at home sampling kits and online data gathering to investigate SARS CoV-2 infections and combine longitudinal syndromic, zero-surveillance, and electronic health record (EHR) data from individuals receiving care in six participating health systems across the United States.
Notable Project Accomplishments:
1) In close consultation with the CDC, we finalized the serology participant eligibility criteria.
2) All six study sites are now actively enrolling participants. Over 25,000 participants enrolled!
3) All six sites successfully delivered EHR data for submission to the Data Coordinating Center. The data was compiled and delivered to the CDC as a preliminary study dataset and represented a major study milestone.
4) Longitudinal cohort serology data is being gathered consistently from all sites
5) Vysnova established processes that would allow for mass outreach campaigns for study participants via the Oracle Eloqua platform for study updates.
